Appco Pharmaceuticals Corp

Appco Pharmaceuticals Corp Drugs

• Klor-con M
  

  ×

  Klor-con M

  

  ---

  Trichomoniasis

  In the FemaleOne-day treatment - two grams of METRONIDAZOLE, USP given either as a single dose or in two divided doses of one gram each, given in the same day.

  Seven-day course of treatment - 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.

  The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.

  Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS). In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation (see PRECAUTIONS-Pregnancy).

  When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.

  In the Male: Treatment should be individualized as it is for the female.

  Amebiasis

  Adults:For acute intestinal amebiasis (acute amebic dysentery):750 mg orally three times daily for 5 to 10 days.

  For amebic liver abscess:500 mg or 750 mg orally three times daily for 5 to 10 days.

  Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.

  Anaerobic Bacterial Infections

  In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially.

  The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.

  The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

  Dosage Adjustment

  Patients with Severe Hepatic Impairment

  For patients with severe hepatic impairment (Child-Pugh C), the dose of METRONIDAZOLE, USP should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS).

  Patients Undergoing Hemodialysis:

  Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation. The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient’s clinical situation (see CLINICAL PHARMACOLOGY).

  Dosage Adjustment

  Patients with Severe Hepatic Impairment

  For patients with severe hepatic impairment (Child-Pugh C), the dose of METRONIDAZOLE, USP should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS).

  Patients Undergoing Hemodialysis:

  Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation. The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient’s clinical situation (see CLINICAL PHARMACOLOGY).

  Close
  More Info